---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Antiretroviral therapy for HIV-associated nephropathy"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Antiretroviral therapy for HIV-associated nephropathy. Topics: Antiretroviral therapy recommendation: KDIGO 2021 glomerular diseases guideline, Antiretroviral therapy and HIVAN: KDIGO Controversies Conference on kidney disease in HIV, Lifetime risk of HIVAN without antiretroviral therapy by APOL1 genotype, and Kidney function after proteinuria onset in people with HIV and high-risk APOL1 genotypes. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/antiretroviral-therapy-for-hiv-associated-nephropathy"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Antiretroviral therapy for HIV-associated nephropathy

<a id="heading-2.2.2.1.6"></a>

## 2.2.2.1.6 Antiretroviral Therapy for HIV-associated Nephropathy

<a id="topic-2.2.2.1.6-1"></a>

### Antiretroviral therapy recommendation: KDIGO 2021 glomerular diseases guideline

> “Recommendation 7.2.3.3.1: We recommend that antiretroviral therapy be initiated in all patients with HIV and CKD, especially biopsy-proven HIV-associated nephropathy (HIVAN), regardless of CD4 count, adjusted to the degree of kidney function (1C).”
> “The quality of the evidence is low, with no RCTs for guidance in patients with HIVAN.”
> “In multivariate analysis, HIVAN risk was reduced by 60% by use of HAART, and no patient developed HIVAN when HAART had been initiated prior to the development of acquired immune deficiency syndrome (AIDS).”
> “Practice Point 7.2.3.3.1: A decision for the use of glucocorticoids as an adjunct therapy for HIVAN must be made on a case-by-case basis, as the risks and benefits long-term are uncertain.”
> “Whether APOL1 risk alleles should be assessed routinely in patients of west African ancestry with HIVAN remains uncertain.”

Source: [KDIGO (2021)](https://kdigo.org/wp-content/uploads/2017/02/KDIGO-Glomerular-Diseases-Guideline-2021-English.pdf)

<a id="topic-2.2.2.1.6-2"></a>

### Antiretroviral therapy and HIVAN: KDIGO Controversies Conference on kidney disease in HIV

> “The classic kidney disease of HIV infection, HIV-associated nephropathy (HIVAN), has become less common with widespread use of antiretroviral therapy (ART); however, there has been a simultaneous increase in the prevalence of other kidney diseases.”
> “Evidence from observational studies strongly supports the beneficial effect of early ART initiation on the risk of classic HIVAN.”
> “Given the overwhelming benefit on survival, ART is recommended for all HIV-positive individuals.”

Source: [Swanepoel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5983378/)

<a id="topic-2.2.2.1.6-3"></a>

### Lifetime risk of HIVAN without antiretroviral therapy by APOL1 genotype

> “We estimate the lifetime incidence for HIVAN of 50% among HIV-infected African Americans with two APOL1 risk alleles who are not receiving antiviral therapy.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

<a id="topic-2.2.2.1.6-4"></a>

### Kidney function after proteinuria onset in people with HIV and high-risk APOL1 genotypes

> “Event-free survival 5 years after proteinuria onset was 53.8% among participants with diabetes and 70.2% among those without diabetes, a difference that was not statistically significant (P = .37).”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
